Print Page   |   Contact Us   |   Sign In   |   Join
News & Press
Filter news by category:

Read about recent events, essential information and the latest community news.

Displaying page 1 of 4
1  |  2  |  3  |  4

Scientific Advancements
Tuesday, December 12, 2017   (0 Comments - view/add)
TapImmune Announces Enrollment of First Patient in Phase 2 Clinical Trial for Treating Triple-Negati »
TapImmune Announces Enrollment of First Patient in Phase 2 Clinical Trial for Treating Triple-Negative Breast Cancer Funde...
Sunday, December 10, 2017   (0 Comments - view/add)
New Data for FDA-Approved CAR T Therapy Show Significant Remission Rates in 42% of Non-Hodgkin Lymph »
New Data for FDA-Approved CAR T Therapy Show Significant Remission Rates in 42% of Non-Hodgkin Lymphoma Patients New ZU...
Wednesday, December 6, 2017   (0 Comments - view/add)
CTD Holdings Receives Rare Pediatric Disease Designation for Trappsol(R) Cyclo(TM) »
CTD Holdings Receives Rare Pediatric Disease Designation for Trappsol(R) Cyclo(TM) ALACHUA, FL -- 12/06/17 -- CTD...
Monday, December 4, 2017   (0 Comments - view/add)
Moffitt Cancer Center Treats First U.S. Patient with Newly FDA-Approved CAR-T Therapy »
Moffitt Cancer Center Treats First U.S. Patient with Newly FDA-Approved CAR-T Therapy Yescarta™ for Non-Hodgkin Lym...
Monday, November 27, 2017   (0 Comments - view/add)
OPKO Health Enrolls First Patient in Phase 2B Study of OPK88004 to Treat Benign Prostatic Hypertroph »
OPKO Health Enrolls First Patient in Phase 2B Study of OPK88004 to Treat Benign Prostatic Hypertrophy   Enlarg...
Monday, November 27, 2017   (0 Comments - view/add)
Catalyst Pharmaceuticals Announces Positive Top-Line Results from Second Phase 3 Clinical Trial of F »
Catalyst Pharmaceuticals Announces Positive Top-Line Results from Second Phase 3 Clinical Trial of Firdapse® in Patients w...
Thursday, November 16, 2017   (0 Comments - view/add)
KemPharm Completes Successful End-of-Phase 2 Meeting on KP415 with FDA »
KemPharm Completes Successful End-of-Phase 2 Meeting on KP415 with FDA   All Clinical and Non-Clinical Pr...
Monday, November 6, 2017   (0 Comments - view/add)
TherapeuticsMD Announces Plan to Resubmit the New Drug Application for TX-004HR »
TherapeuticsMD Announces Plan to Resubmit the New Drug Application for TX-004HR BOCA RATON, Fla.--(BUSINESS WIRE)--N...
Thursday, November 2, 2017   (0 Comments - view/add)
Altemia™ Achieves Successful Clinical Results in Pediatric Patients with Sickle Cell Disease (SCD) »
Altemia™ Achieves Successful Clinical Results in Pediatric Patients with Sickle Cell Disease (SCD) Stati...
Tuesday, October 31, 2017   (0 Comments - view/add)
Catalyst Pharmaceuticals Completes Enrollment in Second Phase 3 Trial of Firdapse® in Patients with »
Catalyst Pharmaceuticals Completes Enrollment in Second Phase 3 Trial of Firdapse® in Patients with Lambert-Eaton Myasthen...
Monday, October 30, 2017   (0 Comments - view/add)
HedgePath Pharmaceuticals Completes Enrollment for its Phase 2(b) Trial in BCCNS and Provides Trial »
HedgePath Pharmaceuticals Completes Enrollment for its Phase 2(b) Trial in BCCNS and Provides Trial Update Positive out...
Thursday, October 26, 2017   (0 Comments - view/add)
M2Gen® Announces Bristol-Myers Squibb's Participation in ORIEN Avatar™ Research Program »
M2Gen® Announces Bristol-Myers Squibb's Participation in ORIEN Avatar™ Research Program The ORIEN Avatar Program repres...
Wednesday, October 25, 2017   (0 Comments - view/add)
RTI Surgical® Launches Fortilink®-C IBF System, the First 3D Printed Polymer-based Interbody Device »
RTI Surgical ® Launches Fortilink ® -C IBF System, the First 3D Printed Polymer-based Interbody Device...
Wednesday, October 25, 2017   (0 Comments - view/add)
New Study: 'Double Decker' Antibody Technology Fights Cancer »
New Study: 'Double Decker' Antibody Technology Fights Cancer   JUPITER, Fla. - Oct. 25, 2017 -- ...
Tuesday, October 24, 2017   (0 Comments - view/add)
Minneamrita Announces FDA Clearance of Investigational New Drug (IND) Application and Initiation of »
Minneamrita Announces FDA Clearance of Investigational New Drug (IND) Application and Initiation of a Phase I Clinical Tri...
Thursday, October 19, 2017   (0 Comments - view/add)
Gene editing in the brain gets a major upgrade »
Gene editing in the brain gets a major upgrade October 19, 2017 Scientists develop a new tool for precise g...
Wednesday, October 18, 2017   (0 Comments - view/add)
FDA Approves Yescarta™, Revolutionary CAR-T Immunotherapy for Non-Hodgkin's Lymphoma Patients »
FDA Approves Yescarta™, Revolutionary CAR-T Immunotherapy for Non-Hodgkin's Lymphoma Patients Moffitt Cancer...
Tuesday, October 17, 2017   (0 Comments - view/add)
New Research Opens the Door to ‘Functional Cure’ for HIV »
New Research Opens the Door to ‘Functional Cure’ for HIV JUPITER, FL – October 17, 2017 – In findings that open the do...
Tuesday, October 10, 2017   (0 Comments - view/add)
Moffitt Researchers Discover New Targets for Approved Cancer Drug »
For more information, contact: Lisa Chillura 813-745-1353 Lisa.Chillura@Moffitt.org  ...
Monday, October 9, 2017   (0 Comments - view/add)
Jupiter Medical Center Offers First Of Its Kind Procedure To Treat Adults with Severe Asthma »
Emily Pantelides Jacobson Strategic Communications 904.477.2306/ emily@jacobsonstrategic.com   ...
Thursday, September 28, 2017   (0 Comments - view/add)
CTD Holdings Enrolls First Patient in US Phase I Clinical Trial of Trappsol(R) Cyclo(TM) for Treatme »
CTD Holdings Enrolls First Patient in US Phase I Clinical Trial of Trappsol(R) Cyclo(TM) for Treatment of Niemann-Pick Dis...
Wednesday, September 27, 2017   (0 Comments - view/add)
Lakewood-Amedex Inc. Reports Positive Top-Line Data from Randomized Controlled Phase 1/2a Trial of N »
Lakewood-Amedex Inc. Reports Positive Top-Line Data from Randomized Controlled Phase 1/2a Trial of Nu-3 Antimicrobial in P...
Tuesday, September 19, 2017   (0 Comments - view/add)
Sancilio Pharmaceuticals Company, Inc. (SPCI) Receives Rare Pediatric Disease Designation From the U »
Sancilio Pharmaceuticals Company, Inc. (SPCI) Receives Rare Pediatric Disease Designation From the US Food and Drug Admini...
Monday, September 18, 2017   (0 Comments - view/add)
CTD Holdings Announces Approval of Clinical Trial Application to Conduct Phase I/II Clinical Study o »
CTD Holdings Announces Approval of Clinical Trial Application to Conduct Phase I/II Clinical Study of Trappsol(R) Cyclo(TM...
Wednesday, September 6, 2017   (0 Comments - view/add)
Longeveron Initiates Phase 2b Stem Cell Therapy Trial to Treat Aging Frailty »
Longeveron Initiates Phase 2b Stem Cell Therapy Trial to Treat Aging Frailty MIAMI , Sept. 6, 2017 /PRNewswire/ --&n...
Thursday, August 31, 2017   (0 Comments - view/add)
Oragenics Doses First Patient in Phase 2 Clinical Trial of AG013 for Oral Mucositis »
Oragenics Doses First Patient in Phase 2 Clinical Trial of AG013 for Oral Mucositis Download as PDF August 3...
Friday, August 25, 2017   (0 Comments - view/add)
Heart hormones protect against obesity and insulin resistance »
Public Release:  25-Aug-2017 Heart hormones protect against obesity and insulin resistance Elevated levels o...
Tuesday, August 22, 2017   (0 Comments - view/add)
Jupiter Orphan Therapeutics Receives Orphan Drug Designation for its Trans-Resveratrol Product JOTRO »
Jupiter Orphan Therapeutics Receives Orphan Drug Designation for its Trans-Resveratrol Product JOTROL for Treatment of Fri...
Tuesday, August 22, 2017   (0 Comments - view/add)
Lakewood-Amedex Inc. Completes Clinical Trial Recruitment for Final Cohort of the Company's Phase 1/ »
Lakewood-Amedex Inc. Completes Clinical Trial Recruitment for Final Cohort of the Company's Phase 1/2a Program in Patients...
Tuesday, August 8, 2017   (0 Comments - view/add)
TapImmune Amends Phase 2 Clinical Trial to Focus on Larger Population of Women with Platinum-Sensiti »
TapImmune Amends Phase 2 Clinical Trial to Focus on Larger Population of Women with Platinum-Sensitive Ovarian Cancer with...
Thursday, August 3, 2017   (0 Comments - view/add)
Moffitt: New Research Shows the Power of Radiomics to Improve Precision Medicine »
August 3, 2017   Moffitt: New Research Shows the Power of Radiomics to Improve Precision Medicine &n...
Thursday, August 3, 2017   (0 Comments - view/add)
AGTC Announces U.S. FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigment »
Source: Applied Genetic Technologies Corporation August 3, 2017   AGTC Announces U.S. FDA Orphan Drug...
Monday, July 24, 2017   (0 Comments - view/add)
Xcovery Collaborates with the National Cancer Institute and Children’s Oncology Group for The NCI-CO »
Xcovery Collaborates with the National Cancer Institute and Children’s Oncology Group for The NCI-COG Pediatric MATCH Clin...
Friday, July 14, 2017   (0 Comments - view/add)
StemSynergy Announces Breakthrough in Colorectal Cancer Drug Development »
July 14, 2017 12:12 PM Eastern Daylight Time StemSynergy Announces Breakthrough in Colorectal Cancer Drug Developm...
Tuesday, June 27, 2017   (0 Comments - view/add)
TapImmune Reaches 50% Patient Enrollment Benchmark in Phase 2 Study of Novel T-Cell Vaccine Targetin »
TapImmune Reaches 50% Patient Enrollment Benchmark in Phase 2 Study of Novel T-Cell Vaccine Targeting Triple-Negative Brea...

Displaying page 1 of 4
1  |  2  |  3  |  4

Abbott

BioFlorida, Inc. | 6742 Forest Hill Blvd., Suite 256 | West Palm Beach, FL 33413
(P) 561-653-3839 admin@bioflorida.com
Membership Management Software Powered by YourMembership  ::  Legal